Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan
Open Access
- 6 June 2005
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 36 (3) , 205-213
Abstract
We conducted a nation-wide survey of 112 adult Japanese patients who underwent reduced-intensity stem cell transplantation (RIST) from 1999 to 2002. Underlying diseases included indolent (n=45), aggressive (n=58) and highly aggressive lymphomas (n=9). Median age of the patients was 49 years. A total of 40 patients (36%) had relapsed diseases after autologous stem cell transplantation and 36 patients (32%) had received radiotherapy. RIST regimens were fludarabine-based (n=95), low-dose total body irradiation-based (n=6) and others (n=11). Cumulative incidences of grade II–IV acute graft-versus-host disease (GVHD) and chronic GVHD were, respectively, 49 and 59%. Cumulative incidences of progression and progression-free mortality were 18 and 25%, respectively. With a median follow-up of 23.9 months, 3-year overall survival rates were 59%. A multivariate analysis identified three significant factors for progression, which are history of radiation (relative risk (RR) 3.45, confidential interval (CI) 1.12–10.0, P=0.03), central nervous system involvement (RR 6.25, CI 2.08–20.0, P=0.001) and development of GVHD (RR 0.28, CI 0.090–0.86, P=0.026). RIST may have decreased the rate of transplant-related mortality, and GVHD may have induced a graft-versus-lymphoma effect. However, whether or not these potential benefits can be directly translated into improved patient survival should be evaluated in further studies.Keywords
This publication has 34 references indexed in Scilit:
- A nationwide survey of deep fungal infections and fungal prophylaxis after hematopoietic stem cell transplantation in JapanBone Marrow Transplantation, 2004
- Third EBMT/AMGEN Workshop on reduced-intensity conditioning allogeneic haemopoietic stem cell transplants (RIC-HSCT), and panel consensusBone Marrow Transplantation, 2004
- Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphomaBlood, 2003
- Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow TransplantationBlood, 2002
- Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT)Bone Marrow Transplantation, 2002
- Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantationBlood, 2001
- Allogeneic bone marrow transplantation in aggressive non‐Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM databaseBritish Journal of Haematology, 1999
- Estimation of failure probabilities in the presence of competing risks: new representations of old estimatorsStatistics in Medicine, 1999
- Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data.Journal of Clinical Oncology, 1992
- Regimen-related toxicity in patients undergoing bone marrow transplantation.Journal of Clinical Oncology, 1988